stars 1 stars 2 stars 3

Scinvivo enables optical biopsy for bladder cancer diagnostics. Current imaging techniques for bladder cancer have their limitations, as they only enable the urologist to visualise the bladder wall surface. In 30% of the cases, healthy tissue is incorrectly classified as cancerous. Another limitation is that it is difficult to fully remove a tumor during a surgical procedure, as the borders of the tumor are difficult to visualize. The last limitation is that it is impossible to determine the invasion depth of the tumor with current imaging technologies, while the invasion depth has major impact on the proposed treatment. All these limitation lead to unnecessary, invasive, and costly interventions. Scinvivos technology enables the urologist to improve diagnosis, and thus decreasing the amount of interventions, patient burden, and costs.

Scinvivo B.V. Questions

The Scinvivo B.V. annual revenue was $5.1 million in 2026.

Camile van der Heijden is the CTO of Scinvivo B.V..

9 people are employed at Scinvivo B.V..

The NAICS codes for Scinvivo B.V. are [33, 6211, 621111, 62111, 621, 339, 62].

The SIC codes for Scinvivo B.V. are [801, 80, 384, 38].

Top Scinvivo B.V. Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users